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Objective: In some individuals, coronavirus severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) infection leads to a variety of serious inflammatory symptoms,
including blood clotting and acute respiratory distress. Death due to COVID-19 shows
a steep rise in relation to age. Comorbidities such as type 2 diabetes mellitus (T2DM),
hypertension, and cardiovascular disease also increase susceptibility. It has been reported
that T-cell regulatory dipeptidyl peptidase 4 (DPP4; cluster of differentiation 26 (CD26))
binds to the external spike (S) glycoprotein of SARS-CoV-2 as a receptor, for the viral entry
into the host cell. CD26 is expressed on many cells, including T and natural killer (NK) cells
of the immune system, as a membrane-anchored form. A soluble form (sCD26) is also
found in the blood plasma and cerebrospinal fluid (CSF).
Approach and results: To investigate a possible relationship between sCD26 levels, age
and pathology, serum samples were collected from control, T2DM and age-related demen-
tia (ARD) subjects. A significant reduction in serum sCD26 levels was seen in relation to
age. ARD and T2DM were also associated with lower levels of sCD26. The analysis of
blood smears revealed different cellular morphologies: in controls, CD26 was expressed
around the neutrophil membrane, whereas in T2DM, excessive sCD26 was found around
the mononucleated cells (MNCs). ARD subjects had abnormal fragmented platelets and
haemolysis due to low levels of sCD26.
Conclusions: These findings may help to explain the heterogeneity of SARS-CoV-2 infec-
tion. High serum sCD26 levels could protect from viral infection by competively inhibiting
the virus binding to cellular CD26, whereas low sCD26 levels could increase the risk of in-
fection. If so measuring serum sCD26 level may help to identify individuals at high risk for
the COVID-19 infection.
Introduction
A novel coronavirus, severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) is the cause of the
latest pandemic, characterised with severe acute respiratory syndrome (ARS) and high mortality due to
both a direct cytotoxic viral effect and a severe systemic inflammation [1–3]. SARS-CoV-2 is a member
of the Coronaviridae family, β-coronavirus genus of the B lineage, and is closely related to the severe
acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus
(MERS-CoV), and several bat coronaviruses (CoVs) [4,5]. COVID-19 disease, caused by SARS-CoV-2,
has a considerably worse prognosis in older and obese people, some ethnic populations and with comor-
bidities such as diabetes mellitus, hypertension, cardiovascular disease and chronic lung disease [6–9].
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All coronaviruses (CoVs) utilise a portion of the spike protein called the receptor-binding domain (RBD) to recog-
nise and attach to the surface of human cells, allowing the viral particle to gain entry through the plasma membrane
[10,11]. SARS-CoV-2 uses angiotensin-converting enzyme-2 (ACE2), the same receptor as SARS-CoV, to infect hu-
mans [12]. However, there is recent evidence that the outer membrane spike glycoprotein S1 of SARSviruses binds to
dipeptidyl peptidase 4 (DPP4)/cluster of differentiation 26 (CD26) when entering into the cells of the respiratory tract
[10,11,13,14]. Differential expression of ACE2 and DPP4/CD26 as receptors of spike glycoproteins may help to ex-
plain the heterogeneity of clinical features in people infected with different CoVs [15,16]. For cell entry, SARS-CoV-2 S
protein also requires a protease, such as Furin, Trypsin, human airway trypsin-like protease, cathepsin-L or the trans-
membrane protease serine 2 (TMPRSS2) [16–19]. ACE2 or CD26 may be activated by proteolytic cleavage by TM-
PRSS2 or cathepsin-L in late endosomes in a pH-dependent manner but the virus can also be activated by trypsin-like
proteases at the cell surface in a pH-independent manner [19,20].
DPP4, also known as CD26, is a serine exopeptidase, a multifunctional type-II transmembrane glycoprotein that
presents in a dimeric form on the cell surface. CD26 is multifunctional, highly conserved among mammals and
plays a major role in glucose metabolism [16]. It preferentially cleaves dipeptides from hormones and chemokines
after a proline amino acid residue, thereby regulating their bioactivity [17,18]. CD26, being a proteolytic enzyme
that is expressed in most cell types (particularly in the immune cells, T cells and natural killer (NK) cells), exists in
both membrane-anchored (mCD26) and soluble form (sCD26) [19]. sCD26 is thought to be shed from the mem-
brane into plasma, and still maintains its enzymatic activity. sCD26 is also found in cerebrospinal fluid (CSF), ex-
erting its multifunctional effects through various signalling pathways that induce and regulate inflammatory and
immunological processes [20]. In humans, mCD26 is primarily expressed on lung epithelial cells, endothelial mem-
branes of the pancreas, small intestine, liver, kidney, prostate, placenta and on activated leucocytes [21,22]. Varia-
tions in sCD26 levels in serum have been reported as clinically relevant in several pathophysiological conditions
including in type 2 diabetes mellitus (T2DM) and virus infections [20]. sCD26 has the capacity to degrade incretins,
GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) (both involved in stimulating insulin secretion in
a glucose-dependent manner), as well as the brain natriuretic peptide (BNP), and the chemokine stromal-derived
factor-1α (SDF-1α), involved in cardiovascular function [23,24].
The emergent global spread of SARS-CoV-2 and its grave impact on public health demands an immediate, coordi-
nated effort in biomedical research to increase understanding of the pathogenesis of the virus and its entry into host
cells. The high fatality rate imposes an urgent need for rapid identification of effective treatments including novel
therapeutics, antivirals and vaccines. We screened mCD26 and sCD26 expression to investigate its role in innate
immunity and inflammation [25]. To achieve this, we included samples from T2DM [24] and age-related dementia
(ARD) subjects who are considered at high risk for COVID-19 and share some pathological features [26,27]. Via anal-
ysis of CD26 involvement in various clinical and pathological conditions that are also characteristic of COVID-19,
we provide circumstantial evidence for sCD26 implication in viral infections, such as SARS-CoV-2.
Materials and methods
Ethics and participants
Ethics and Research and Development (R&D) approvals were granted by the National Research Ethics Committee of
the East of England. Cambridge Health Authorities Joint Ethics Committee granted ethical approval for use of human
brain tissue and serum samples (project reference number: REC:15/WM/0379). Written consents were obtained from
controls, adults with diabetes participants and subjects with ARD with the capacity to consent. Verbal assent was
obtained from participants with ARD lacking capacity to provide written assent, and this was provided instead by an
appointed consultee, in accordance with the Mental Capacity Act of the U.K. (2005). Information on older controls
(OCs; n=50) and ARDs (n=50) has already been disclosed in a previous publication [28].
Paraffin-embedded sections of human brain
Human brain sections of young and aged postmortem CNS-diseased, were provided by the Cambridge Brain Bank
under the project reference number REC:15/WM/0379.
Blood and serum/plasma collection
Whole blood, serum and plasma samples from human younger controls (YCs: n=50, aged between 30 and 55 years),
and OCs (n=50, aged between 56 and 85 years), middle-aged type II diabetes (T2DM, non-demented, n=50, aged
between 30 and 55 years) (please note that none of the control subjects had a clinical diagnosis of dementia) and
ARD (OD, n=50, aged between 56 and 85 years) were collected for DNA and protein analyses. All blood samples
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were collected for serum in BD vacutainer SST advance tubes (containing inert gel barrier and clot activator coating).
Serum and plasma were separated immediately by centrifugation at 2465×g for 6 min at 4◦C, aliquoted and stored at
−80◦C until analysis.
Blood slide preparation
A drop of blood placed on a slide was spread as described previously [29]. The slide was air-dried and fixed in 100%
methanol and stored at 4◦C. Further investigations, including immunohistochemistry (IHC), were performed on
stored fixed slides as described later.
Animals
Three months old C57/Bl6 mice were purchased from Charles River and bred for the experiments at University of
Cambridge Bioscience Facility (UBSS, at John van Geest Centre for Brain Repair Animal Facility). All experiments
were performed according to the ‘Animal (Scientific Procedures) Act 1986’ and the ‘Guidance of the Operation of
ASPA 2014’, and were approved by the Ethical Committee of the U.K. Home Office (PPL number 70/7920).
Mice tissue preparation
All animals were housed under standard conditions (12-h light–dark cycle, 20◦C ambient temperature) with free ac-
cess to food and water. Animals undergoing perfusion were anaesthetised with raising concentrations of CO2 followed
by terminal injection of Euthatal (0.3 ml per 100 g of body weight). Collection of fresh tissues was performed after rais-
ing the concentration of CO2 followed by cervical dislocation. For histochemical analyses, animals were anaesthetised
with pento-barbitone and flash-perfused transcardially with 0.9% saline followed with 4% (v/v) paraformaldehyde
(PFA) in 0.1 M phosphate buffer saline (PBS; pH 7.4). Brains were removed, post-fixed for 4 h in the same fixative, and
then cryoprotected with 30% sucrose in 0.1 M PBS. Brains and other tissues (spleen and duodenum) were sectioned
by microtome as described previously [28]. For in situ hybridisation (ISH), unfixed tissues were carefully dissected
from C57/Bl6 mice from various brain regions and different organs including spleen, lung, duodenum and embryos
(embryonic day 18, ED 18) and snap-frozen in dry ice until analysed by ISH.
ISH
Brain tissues and other organs were prepared for ISH and probed as described previously [30]. To synthesise
DIG-labelled RNA probes, the target CD26 cDNA was amplified by PCR using primers designed on the basis of
the mouse CD26 cDNA sequence used in RT-PCR. The primers used for DIG labelling were:
CD26-insF: TAATACGACTCACTATACAAGAAATATCCTCTACTATTAG CD26-insR: ATTTAGGTGACAC-
TATAGAGAAATCCACTTCCAACATCGAC sequenced and homology checked by BLAST search (NCBI database).
In vitro transcription reactions were performed using dig-UTP RNA labeling mix and SP6 or T7 RNA polymerase
(Roche, Mannheim, Germany).
ISH with DIG-labelled probe was carried out on spleen, brain and other embryonic tissues’ sections fixed in 4% PFA
for 10 min, permeabilised for 10 min in (0.1 M PBS with 0.5% Triton X-100), and acetylated by 10-min incubation in
triethanolamine solution. Pre-hybridisation was performed in hybridisation buffer for 3 h at 62◦C and then hybridised
with DIG-labelled probes (100 ng/ml) in the same buffer overnight at 62◦C. Stringent washing was performed in
0.2× SSC for 1 h at 62◦C. For the detection of DIG-labelled hybrids, the slides were equilibrated in maleic acid buffer
(MAB, 0.1 M maleic acid and 0.15 M NaCl, pH 7.5), incubated for 1 h at room temperature (RT) with 1% blocking
reagent made in MAB (blocking buffer), and then for 1 h with alkaline phosphatase-conjugated anti-DIG antibodies
(Roche, Mannheim, Germany) diluted 1:5000 in blocking buffer. The slides were washed twice for 30 min in MAB
and incubated overnight in colour development buffer [2.4 mg levamisole (Sigma), 45 μl 4-nitroblue tetrazolium
(Sigma), and 35 μl 5-bromo-4-chloro-3-indolyl-phosphate (Sigma) in 10 ml of a buffer made of 0.1 M Trizma base,
0.1 M NaCl and 0.005 M MgCl2, pH 9.5]. The reaction was stopped in neutralising buffer (0.01 M Trizma base and
0.001 M EDTA, pH 8) and sections were mounted in PBS/glycerol and a coverslip applied over the section on the
slide. Non-specific binding was analysed using sense probes.
Solid-phase enzyme-linked immunosorbent assay
The sCD26 plasma concentration was measured with the human DPPIV/CD26 DuoSet ELISA development System
kit (R&D Systems, Catalogue number DY1180) according to the manufacturer’s instructions. Briefly, for the detection
of sCD26, in 96-well culture plates were incubated overnight with monoclonal antibody (mAb) anti-CD26 capture
antibody (1 μg/ml) (R&D systems, catalogue number 842127). The following day the plates were washed three times
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with washing buffer (0.05% Tween 20 in 0.1 M PBS pH 7.4) and blocked in blocking solution (1% BSA and 0.05%
Tween 20 in 0.1 M PBS) for 2 h at RT. After blocking, the plates were washed three times with washing buffer and
loaded with 10 μl plasma into 90 μl blocking solution and incubated 4 h at RT. All experiments were performed
in quadruplicate unless otherwise specified. A recombinant human protein (R&D, Catalogue number 842129) was
diluted in assay buffer in a two-fold serial dilution and used for the standard curve with a concentration range of
1000, 500, 250, 125, 62, 31, 15, and 0 pg/ml. After 4 h of incubation, the samples were removed and the plates were
washed three times for 5 min with washing buffer before incubation for 2 h at RT for detection with a biotinylated
rabbit monoclonal anti-human CD26 (catalogue number 842128, R&D) antibody (1μg/ml) diluted in blocking buffer.
After three further washing steps, the plates were incubated with anti-rabbit HRP-conjugated secondary antibody
(1:4000) for 1 h followed by three washes. A total of 100 μl of 1-Step ULTRA tetramethylbenzidine (TMB-ELISA,
Thermo Scientific) was added for ∼30 min at RT. Finally, 100 μl of 2 M H2SO4 was added to quench the reaction.
Colorimetric quantification was performed with an Infinite m200 plate reader (Tecan) at 450/540 nm.
Antibodies
The following primary antibodies were used: mouse monoclonal anti-CD26 (mAb M-A261, Invitrogen) and rabbit
polyclonal (pAb) anti-CD26 antibody (Abcam, Ab28340). Other antibodies used in the present study were rabbit
pAb anti-apolipoprotein-E (ApoE; Abcam, Ab85311), anti-CD3 (PA5-32318) Thermo Fisher Scientific, anti-cluster
of differentiation 42b (CD42b; Abcam, Ab104704), anti-rabbit polyclonal glycophorin (Abcam, 196568), anti-divalent
metal protein 1 (DMT1; Abcam, Ab123085), anti-ferroportin (FPN; Abcam Ab85370), anti-GFAP (Abcam Ab48050),
anti-CD68 (Sigma–Aldrich, AMAB98073), and anti-CD11b (Thermo Fisher, mAbM1/70). The following secondary
antibodies were used: biotinylated goat anti-rabbit-Ig and biotinylated horse anti-mouse (both from Vector Laborato-
ries, 1:250 for IHC); Alexa Fluor 568-labelled donkey anti-mouse-Ig, Alexa Fluor 488-labelled donkey anti-rabbit-Ig,
and Alexa Fluor 568-labelled donkey anti-goat-Ig (all from Invitrogen, 1:1000 for immunofluoresence).
Immunofluorescence
Brain and other sections were blocked using blocking buffer (0.1 M PBS, 0.3% Triton X-100, 10% normal
donkey serum) for 1 h at RT, then incubated overnight at 4◦C with primary antibody diluted in blocking
buffer. Alexa Fluor-conjugated secondary antibodies were used for detection and samples counterstained with
4′,6-diamidino-2-phenylindole (DAPI, Sigma). Sections were then mounted on glass slides with coverslips using Flu-
oro Save (Calbiochem).
Microscopy
Bright-field images were taken and quantified using Lucia imaging software and a Leica FW 4000 upright microscope
equipped with a SPOT digital camera. Fluorescence images were obtained using a Leica DM6000 wide-field fluores-
cence microscope equipped with a Leica FX350 camera with ×20 and ×40 objectives. Images were taken through
several z-sections and de-convolved using Leica software. A Leica TCS SP2 confocal laser-scanning microscope was
used with ×40 and ×63 objectives to acquire high-resolution images.
Image and statistics analyses
Data were analysed by the paired Student’s t test (two-tailed) for two-group comparison, or by ANOVA test for mul-
tiple comparison testing. Values in the figures are expressed as mean +− SEM. A one-way ANOVA was used for com-
parison of data among control, T2DM and ARD and conducted with IBM-SPSS statistic 19 software. Significance was
analysed using GraphPad and P-values ≤0.001 were considered significant and are indicated in the corresponding
figures and figure legends.
Results
sCD26 serum protein levels are reduced in dementia, diabetes and in
older people
To explore the level of sCD26, serum samples from young and old controls [age-matched T2DM: n=50, 30–55 years;
non-demented) and ARD (n=50, aged between 56 and 85 years) subjects were analysed by sandwich enzyme-linked
immunosorbent assay (ELISA) using Human DPP4/CD26 (R&D system, catalogue number: DY1180). All samples
were analysed on the same day, using same standard to reduce the day-to-day variation.
Levels of sCD26 were lower in older subjects as well as in patients with comorbidities such as T2DM and ARD.
The serum protein analysis by ELISA showed that the mean level of sCD26 in control subjects was higher than seen
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Table 1 Soluble Serum CD26 levels in young vs old controls, diabetics and old demented subjects measured by ELISA
Serum CD26 (pg/ml) YC Young diabetic OC Old demented
Average (pg/ml) 901.26 402.88 664.22 216.88
Two-way ANOVA Ordinary
Alpha 0.05
Source of variation % of total variation P-value P-value summary Significant
Row factor 5.504 0.6493 ns No
Column factor 76.25 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P-value
Row factor 970863 49 19814 F (49, 147) = 0.9051 P=0.6493
Column factor 13450000 3 4483000 F (3, 147) = 204.8 P<0.0001
Residual 3218000 147 21890
Number of missing values 0
Tukey’s multiple
comparisons test
Mean Diff. 95% CI of diff. Significant Summary Adjusted P-value
YC vs. Young diabetic 498.4 (pg/ml) 421.5–575.3 (pg/ml) Yes
YC vs. OC 237 (pg/ml) 160.2–313.9 (pg/ml) Yes **** <0.0001
YC vs. Old demented 684.4 (pg/ml) 607.5–761.3 (pg/ml) Yes **** <0.0001
Young diabetic vs. OC –261.3 (pg/ml) −338.2 to −184.4 (pg/ml) Yes **** <0.0001
Young diabetic vs. Old
demented
186 (pg/ml) 109.1–262.9 (pg/ml) Yes **** <0.0001
Old control vs. Old
demented
447.3 (pg/ml) 370.4–524.2 (pg/ml) Yes **** <0.0001
in their older counterparts (901.3 vs 664.2 pg/ml, R2 = 0.6, P-value ≤0.0001) in YC and OC respectively (Table 1).
In younger T2DM, the mean level was (402.9 pg/ml, compared with the mean level in ARD of 216.8 pg/ml, R2 = 0.7,
P-value ≤0.0001) (Figure 1A). A significant reduction in serum sCD26 levels was seen in ARD and in T2DM subjects
compared with age-matched controls (Figure 1A and Table 1).
CD26 mRNA expression pattern identified in immune cells
Using ISH with a DIG-labelled sense and antisense CD26 probes, we visualised the cellular location of CD26 mRNA
in freshly frozen human tonsil, mouse heart, pancreas, embryonic and adult spleen, duodenum, liver, lung and pla-
centa, as shown previously (see ‘Materials and methods’ section) [29]. There was no non-specific binding with sense
probe (Figure 1B), whereas with the antisense probe, a predominant staining in the outer darker T cells region of the
lymphoid follicle was observed with much less staining in the inner area of the germinal centre (Figure 1C). Higher
mRNA expression was seen in the embryonic tissues (in the endothelial layer of the heart, pancreas and spleen)
(Figure 1D–F). The highest levels were seen in the placenta, in trophoblast cells, in the spleen, in the duodenum, par-
ticularly in the intestinal epithelial cells (Figure 1G–I,K). The membrane-bound mRNA levels was also visible in the
lung epithelial cells (Figure 1J). However, very limited mRNA was seen in the mouse brain tissues (Figure 1L), except
in blood vessels, sub-ventricular zone (SVZ) and choroid plexus (CP) epithelial cells (Figure 1M–O). Together, these
findings indicate that CD26 mRNA is expressed in T cells, epithelial and endothelial cells of many different organs.
CD26 protein is expressed in the CP epithelial cells and meningeal blood
vessels
COVID-19 infection affects epithelial and endothelial lining of the lung and meningeal macrophages as well as other
cells of the immune system [31,32]. For validation of CD26 protein levels in the brain and other immune cells, tissue
sections were stained by immunofluorescence (IF) using anti-CD26 mouse mAb (M-A261, Invitrogen) and analysed
using confocal microscopy. A clear signal was seen in the human spleen white pulp, very close to the central canal
and the T-cell area surrounding the lymphoid follicles (Figure 2A–C). CD26 and CD3 (a marker expressed in T cells)
colocalised in the outer darker region of the germinal centre containing large- and medium-sized T lymphocytes
(Figure 2C).
There was no visible mRNA expression of CD26 in the adult human or mouse brain, but unexpectedly high levels of
proteins were observed in the human CP epithelial cells and meningeal blood vessels (Figure 1M,O). CD26 protein
expression was present in the mouse embryonic CP (Figure 2D), human CP epithelial cells and macrophages that
colocalised with ApoE (Figure 2E). CD26 protein was seen in the perivascular macrophages and colocalised with
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 1. sCD26 serum protein levels are reduced in dementia, diabetes and in older people
(A) The ELISA analysis performed with human serum showed that CD26 levels were highest in the YCs, followed by OCs, sig-
nificantly decreased in young diabetics (T2DM) and lowest in the ARD (OD). (YC vs T2DM, and OC vs OD, P≤0.0001; YC vs OC,
P≤0.001 (P≤0.001*** and P≤0.0001 showed with ****). All serum samples were analysed at the same time to reduce the day-to-day
variation. CD26 mRNA expression was detected by ISH using sense and antisense DIG-labelled CD26 probe. A sense probe was
used to investigate non-specific binding in tonsil section, no non-specific binding was observed (B). Localisation of CD26 enzyme
activity in tonsils, a predominant staining of CD26 mRNA was observed in the outer darker extra-follicular T cells region of tonsil
with much less staining in the inner germinal centres (C), in the endothelium of heart of ED 18 (D), endothelial layer of pancreas
(E), embryonic spleen (F), in adult spleen (G). In adult mouse duodenum, CD26 expressed in the epithelial brush border (H), around
the hepatocytes in the liver (I), in the lung epithelial cells (J) and in the placental trophoblast cells (K), (cellular localisation of mRNA
indicated by arrow in all panels). There was no mRNA visible in the mouse brain cells (L), whereas present in the brain parenchymal
blood vessels (M), in sub-ventricular zone (SVZ) (N) and in the choroid plexus (CP) (O). Together, these findings indicated that CD26
mRNA is expressed in T cells, epithelial and endothelial cells of many different organs. Scale bar: (B–F,H–J = 50 μm, K–O = 100
μm).
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Figure 2. CD26 protein is expressed in the CP epithelial cells, meningeal blood vessels and bind with divalent metal proteins
in the duodenum
Double IFC staining was performed in the human spleen using mouse mAb anti-CD26 (Green) and rabbit polyclonal (pAb) anti-CD3
(red), and DAPI for nuclei (blue) (A–C). CD26 immunoreactivity was seen in the human spleen in white pulp, very close to the central
canal and in T-cell area surrounding the lymphoid follicles (A,B). CD26 and CD3 (a marker expressed in T cells) colocalised in the
outer darker region of the germinal centre containing large- and medium-sized T lymphocytes and both proteins colocalised (C).
Embryonic mouse CP was stained with CD26 (green) and DAPI (blue) and imaged using confocal microscopy. Very high CD26
expression was present in the mouse embryonic CP epithelium (D). Human normal brain section particularly CP was stained with
CD26 (green) and ApoE (red), both proteins were present in the CP epithelial membrane and colocalised in the macrophages (E).
A mouse brain section from lateral ventricle stained with CD26 (red) and a macrophages marker CD68 (green), CD26-positive
macrophages were visible at the wall of ventricle and in the CP, both proteins colocalised (F). An ARD brain section from cortex,
close to a blood vessel was stained with CD26 (green) and astrocyte marker (GFAP, red), showed that CD26 protein carried by
RBCs and macrophages entering through damaged blood vessels (BVs), surrounded by GFAP-positive astrocytes (G). Another
blood vessel in the brain stained with CD26 (green) visible in the epithelium (H). A human brain section from frontal cortex stained
with CD26 (red) and a microglial marker CD11b (green) colocalised in the meningeal macrophages in the Pial surface of cortex (I).
Cellular localisation of CD26 protein indicated with white arrow in all panels). Duodenum sections from adult mouse was stained
with CD26 (green) and DAPI (blue), visible in the columnar cells within the crypts (J), and colocalised with metal-binding protein
DMT1 at the apical surface (K). Large populations of T lymphocytes positive for CD26 colocalised with another metal-binding
protein FPN at the basolateral site and in the central core of lamina propria containing blood vessels (L). Scale bar in (A–F) = 40
μm, (G–L) = 25 μm. Abbreviation: RBC, red blood cell.
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CD68 (a known peripheral macrophage marker) in lateral ventricle (Figure 2F). It was visible in the epithelial layer
of blood vessels (Figure 2H). When human brain sections (n=6) from ARD subjects were stained with CD26 and an
astrocyte marker with GFAP antibody, sCD26 protein was detected in the wall of blood vessels: presumably sCD26
which entered the brain parenchyma from blood vessels via astrocytes (Figure 2G,H). CD26 was detected in the
meningeal macrophages colocalised with CD11b, a monocyte/microglial marker (Figure 2I).
Membrane-bound CD26 protein binds with divalent metal proteins in the
duodenum
Although SARS-CoV-2 may primarily enter through the lung’s epithelial cells, the small bowel may also be an im-
portant entry point or an interaction site [33]. Our in situ data (Figure 1H) revealed prominent CD26 expression in
the small intestine (duodenum and jejunum). We immunostained mouse gut tissues with CD26 antibody and other
known duodenal membrane-binding protein markers, DMT1 and FPN to assess the expression further [34,35]. The
most distinct feature of the small intestine is the mucosal lining, with brush border villi and crypts, lined with colum-
nar cells. CD26 staining was seen in the columnar cells within the crypts, particularly in the apical surface and colo-
calised with metal-binding protein, DMT1, at the apical surface (Figure 2J,K). Large populations of T lymphocytes
positive for CD26 colocalised with another metal-binding protein (FPN) at the basolateral site and in the central core
of lamina propria containing blood vessels (Figure 2L). Throughout the small intestine, confluent lymphoid tissues
known as Peyer’s patches were visible and CD26 positive (Figure 2L).
CD26 and coagulopathy
One of the emerging hallmarks of COVID-19 is a coagulopathy, termed as ‘sepsis-induced coagulopathy’ (SIC) with
elevated D-dimer and fibrinogen levels [36]. It is related to an infection-induced systemic inflammatory response with
endothelial dysfunction and microthrombosis often leading to organ failure [36–38]. Several observational studies
have characterised monocytes during SARS-CoV-2 infection [39]. We investigated cellular expression of CD26 in
blood smears from different age groups (n=20, age between 30 and 85 years) and imaged using confocal microscopy.
The blood smears from young and old subjects were co-labelled with CD26 monoclonal antibody and either with
an erythrocyte plasma membrane marker (glycophorin) or a platelet marker (CD42b). Glycophorin was expressed
on the surface of red blood cells (RBCs) (Figure 3A–C) with CD26 seen around the RBCs (could be on erythrocytes
spikes) (Figure 3A,B). There was stronger CD26 expression around the RBCs membranes in the controls (Figure
3A,G) and in T2DM compared with ARD (Figure 3B,C). CD26 was expressed on the surface of mononucleated
cells (MNCs) around the outer membrane (Figure 3D,E), and a web-like appearance that colocalised with integrin
CD42b protein was observed (Figure 3F). The control subjects had stronger CD26 expression around the neutrophil
membrane (Figure 3D,G,J), whereas in T2DM there was excessive sCD26 around the MNCs and haemolysis in RBCs
(Figure 3H,K). The young and old control subjects expressed much more CD26 in MNC (Figure 3D,G,J,L), whereas
younger T2DM and older ARD subjects carried abnormal fragmented platelets stained with CD42b (Figure 3H,I).
Additionally, scattered sCD26 was observed extracorporally of RBCs and within MNCs in the T2DM samples (Figure
3H–K). A classic dysmorphology (bilobed neutrophils) was frequently seen in blood of T2DM (Figure 3H,K) whereas
normal neutrophils positive for CD26 were found in controls (Figure 3D–G).
In ARD subjects (with dementia), RBCs appeared abnormally shaped (macrocytic with damaged erythrocytes
spikes) and platelets found were fragmented (Figure 3F–I). These findings suggest that further investigation of CD26
involvement in lymphocyte regulation is warranted, especially in relation to the coagulation cascade.
Discussion
COVID-19 caused by SARS-CoV-2 is now a pandemic [2,3,40]. SARS-CoV-2 pathology is similar to that of
SARS-CoV- and MERS-CoV-induced viral pneumonia [41]. CoV has specific immune response and immune escape
characteristics and can cause severe pathogenic mechanisms through inflammation leading to a variety of symptoms
like acute respiratory distress syndrome, gastrointestinal disorder, renal failure, vascular bleeds, stroke, T cell-specific
immune responses and cytokine storm [4,42,43]. Cytokine storm is hypercytokinemia that increases the volume of
pro-inflammatory cytokines in the serum (e.g. IL-1β, IL-6, IL-12, INF-γ) and chemokines (CXCL10 and CCL2),
and is correlated with pulmonary inflammation and extensive lung involvement as seen in COVID-19 patients [44].
MERS-CoV infection was also described to provoke increased concentration of cytokines (IL-15, IL-17, TNFα and
INF-γ) [45]. It is reported that victims infected with SARS-CoV-2 also demonstrate high levels of IL-1β, TNFα,
INF-γ, CXCL10 and CCL2 which may be attributed to the activated response of T helper 1 (Th1) cells [46]. CXCL10
binds to CXCR3, a G-protein-coupled receptor, which is known to be expressed on activated T lymphocytes, NK cells
8 © 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. CD26 is expressed on the surface of MNCs around the outer membrane, and a web-like appearance that colo-
calised with integrin observed
The blood smears from normal, T2DM and ARD were stained with CD26 (green) and either glycophorin (red) or CD42b (red) and
imaged using confocal microscopy. In normal blood smears, glycophorin was expressed on the surface of RBCs (A) and CD26
seen around the RBCs in T2DM and ARD (B,C). Blood smear showed normal MNCs surrounded by CD26 (green) and CD42b (red)
in normal platelets (red) (D), in T2DM (E) and in ARD (F). In T2DM, there was excessive sCD26 around the MNCs and some clumped
platelets (red) in the periphery (H–K). Demented (ARD) subjects showed a web-like expression of CD26 proteins (green) present
surrounding the neutrophil and granulocytes (F), and fractured platelets (red) around the MNCs with visible nets of integrin (I). One
old control blood smear stained either with CD26 (green) and either with glycophoryn or CD42b (red). CD26 was present around
the MNCs (G) and some platelets colocalised with CD26 and CD42b (J). Cellular localisation of CD26 protein indicated with white
arrow in all panels). CD26 level was highest in the controls, lower in T2DM and lowest in the ARD (L). Scale bar in A–K = 10 μm.
***P≤0.001, ****P≤0.0001.
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and some epithelial and endothelial cells. CXCL10–CXCR3 acts in an autocrine fashion on the oxidative burst and
chemotaxis in the inflamed neutrophils, leading to fulminant pulmonary inflammation [47].
Recently, sequence and modelling analyses of S glycoproteins of MERS-CoV, SARS-CoV-2 and further
co-purification with the MERS-CoV S1 domain, identified that CD26 functions as a cellular receptor for MERS-CoV
and possibly SARS-CoV-2 [16,48]. Another recent study reported a correlation between CD26 and ACE2, suggesting
that both membrane proteins could be relevant in the pathogenesis of virus entry [49]. The co-expression of ACE2
and CD26 as receptors of spike glycoproteins suggests that different human CoVs may target similar cell types across
different human tissues, and this may also explain the presence of similar clinical features in patients infected with
different CoVs. In addition, it was shown that CD26 acted as a CoV co-receptor, thus suggesting a potential similar
mechanism of entry for SARS-CoV-2. There is a connection between the SARS-CoV, SARS-CoV-2, ACE2 and the
rationale for soluble ACE2 as a potential therapy by using ACE2+-small extracellular vesicles (sEVs) [50]. We suggest
that soluble CD26 circulates via platelets and T cells carrying vesicles as shown in the normal blood smear (Figure
3).T herapeutic approaches may be envisaged using sCD26 as a decoy receptor which could inhibit the entry of the
virus through cell surface [16,50,51]. In this study, we analysed the expression pattern in healthy subjects and subjects
who are at high risk for COVID-19. Our findings now need to be validated with COVID-19 patients.
The role of CD26 in immune regulation has been extensively characterised, with findings elucidating its linkage
with signalling pathways and structures involved in T-lymphocyte activation as well as antigen presenting dendritic
T-cell interaction [52,53]. In this study, we show that CD26 is expressed in T cells, the extrafollicular area of tonsil
and at T-cell areas in the germinal centre of the spleen and is also colocalised with CD3 [54]. The outer darker region
of the germinal centre of tonsil, showed that it contained large- and medium-sized lymphocytes as described before
[54]. Spleen may be one of the organs directly attacked by the virus in some patients who died from COVID-19. T and
B lymphocytes in the spleen decreased in varying degrees, lymphoid follicles are atrophied, decreased or absent [55].
T cells secrete cytokines and chemokines in immune cells as reported in some genes present in MHC region [56].
These findings suggest that the binding of sCD26 to the spike (S) glycoprotein may also depend on T-cell population.
Although SARS-CoV-2 may primarily enter the cells of the lungs, the small bowel may also be an important site
of entry or interaction site, as the enterocytes are rich in ACE2 receptors [33]. Duodenal mucosa expresses mCD26
particularly on the apical site of the brush border epithelial cells where T cells present and bind with many divalent
metals including Fe+, Ca+, Co+, Zn+ and Hg+ [57]. Particularly, iron (Fe+) plays an important role in inflammation
and causes disbalance and hyperferritinaemia in COVID-19 [58]. Most iron absorption occurs in the duodenum
via the DMT1-mediated uptake and FPN1-mediated export across the apical and basolateral membranes respec-
tively [34,35]. CD26 is a cysteine-rich protein, that can bind with divalent metal-binding proteins (DMT1) and FPN
[28,34,35]. Much of this research focus has centred on the ectodomain of the spike protein. The ectodomain is an-
chored to a transmembrane region, followed by a cytoplasmic tail. Recently, it was reported that a sequence similarity
exists between the cysteine-rich cytoplasmic tail of the CoV spike protein with the cysteine-rich domain in hepcidin
protein, which is a key regulator of iron homoeostasis in humans and other vertebrates has been reported [59–61].
SARS-CoV-2 spike (S) glycoprotein can bind DMT1 on the apical site of brush border epithelial cells in the gut mu-
cosa, and could mediate membrane fusion and virus entry into the cells. High levels of sCD26 can therefore potentially
compete and prevent viral entry through gut mucosa and exert beneficial immunoprotective effects via elevation of
GIP, a peptide that is produced in gastrointestinal K cells and further proteolysed by CD26 [62]. As a consequence,
the small bowel may serve as a viral entry site or as a potentiating organ, magnifying the systemic inflammatory re-
sponse, small bowel being the largest lymphoid organ of the body. A significant proportion of COVID-19 patients
with gastrointestinal symptoms clearly support the involvement of the small bowel in SARS-CoV-2 [33].
One of the emerging hallmarks of COVID-19 is a coagulopathy, termed as ‘SIC’ with elevated D-dimer and fib-
rinogen levels [36]. It was shown that platelet activation and platelet–leucocyte interactions participate in the patho-
physiology of viral infections, including dengue, HIV and influenza [63]. Recently, a hypercoagulability state has
been reported as a major pathologic event in COVID-19, and thromboembolic complications are listed among
life-threatening complications of the disease [64]. Platelets are chief effector cells of haemostasis and pathological
thrombosis [65]. In this paper, we demonstrated that increased platelet activation and platelet–monocyte aggregate
formation are observed in diabetic subjects (Figure 3E,H), and much more prominent in ARD (Figure 3F,I) but not
in controls (Figure 3D,G).
Recent clinical evidence has revealed T2DM and cardiovascular risk factors increase susceptibility to COVID-19
infection [66]. The elderly, and those with underlying medical conditions particularly obesity, diabetes, ARD are the
pre-existing diseases associated with the greatest risk and death in COVID-19 pandemic [26,27,67]. We therefore
chose T2DM, ARD and age-matched young and old controls who are at high risk for COVID-19 infection. They all
could thus have common risk factors that affect different organs, particularly the epithelial membrane responsible
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for the viral entry. We found that CD26 is expressed in the epithelial membrane of the CP and in the endothelium of
blood vessels in the brain. The CP is a secretory tissue responsible for producing both the CSF in the vertebrate brain
and many innate immune molecules to protect the brain from infection by surveying the blood–brain barrier (BBB)
[29,68]. CD26 protein is present in the CP epithelial membrane and in the outer layer of brain pia mater particularly in
the meningeal macrophages, where it is colocalised with other brain spectrins, known as fordin and ankyrin [29,69].
Similarly, CD26 is expressed in erythrocyte membranes (also having erythrocyte spikes) and is colocalised with mem-
brane proteins, glycophorin and integrin α2β3 [70]. Since SARS-CoV-2 spike (S) glycoprotein binds to erythrocytes,
causing clotting defects in the small blood vessels [37,71], we analysed blood smears from young, diabetic (T2DM)
and older subjects (ARD). In young controls, the higher levels of sCD26 around neutrophils, and in platelets was seen,
whereas in immunocompromised T2DM subjects many fractured platelets and clumped RBCs with haemolysis were
visible, alongside a web-like expression of integrin proteins was present surrounding the neutrophil and granulocytes
(also visible in ARD subjects). Furthermore, in ARD subjects macrocytic, broken RBCs and fragmented platelets were
present. These findings demonstrated the impaired coagulopathy in older subjects and those with T2DM and demen-
tia, and complement our previous findings of another immunoprotective molecules such as TREM2, suggesting that
CD26 may also be required for the haemopoietic cellular growth and protection [72].
Levels of serum CD26 are approximately three-times higher in pregnant women at ∼3μg/ml (R.R.-C., unpublished
data). CD26 mRNA expression is elevated in placental trophoblasts, where it may induce regulatory T cell (Treg)
differentiation and protect the foetus from external infections [73]. These findings suggest that newborn babies and
young children may be protected from COVID-19 due to high levels of sCD26. Another study reported female HIV
positive but disease-free sex-workers in Nairobi also showed higher levels of serum sCD26 and thereby presumably
protecting them from all other viral infections [74]. Our findings suggest that T-cell regulatory CD26 is expressed
in different organs from tonsil, spleen, gut mucosa to brain (particularly in CP and in BBB) and sCD26 may play a
crucial role as a decoy receptor which could inhibit the entry of the virus through cell surface, allowing more time for
neutralising antibodies to be raised against the SARS-CoV-2 spike protein.
Conclusions
We have shown sCD26 expressed in serum, and mCD26 in T cells (in tonsil and spleen), in CP, duodenum and ery-
throcytes. We observed a significant reduction in serum sCD26 levels with age and in T2DM subjects compared with
age-matched controls. Thus, we suggest that measuring sCD26 level in the serum of young and old control subjects
and comparing them with SARS-CoV-2 virus carrying subjects could be explored as a possible test for inflammatory
stages in COVID-19: high serum sCD26 level could protect from viral infection by blocking the receptor from virus
entry, whereas low sCD26 level may be associated with a higher risk of infection. If correct,a therapeutic approach
may be to use sCD26 as a decoy receptor which could competitively inhibit the entry of the virus through cell surface.
Perspectives
• The rapid global spread of SARS-CoV-2 and its grave impact on public health immediately demands
prompt and efficient coordinated effort in biomedical research to increase the understanding of the
pathogenesis of the virus and its impact upon the host cells. T2DM and cardiovascular risk factors
increase the susceptibility to COVID-19 infection. Variations in sCD26 levels in serum have been
reported as clinically relevant in several pathophysiological conditions including T2DM and virus in-
fections, where CD26 may plays a critical role in the innate immunity and T-cell regulation.
• We investigated the mCD26 and sCD26 expression to uncover CD26 role in the innate immunity and
inflammation. For this, we analysed samples from T2DM and ARD subjects who are considered at
high risk for COVID-19. We show sCD26 is expressed in serum, T cells (in tonsil and spleen) whereas
mCD26 in CP, duodenum and erythrocytes.
• We suggest that measuring sCD26 level in the serum should be explored as a possible test for inflam-
matory stages in COVID-19: high serum sCD26 level could protect from viral infection by blocking the
receptor from virus entry, whereas low sCD26 level may be associated with a higher risk of infection.
It could be theraputic approches to use sCD26 as a decoy receptor which could competitively inhibit
the entry of the virus through cell surface.
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